William Blair Equities Analysts Increase Earnings Estimates for FibroGen, Inc. (NASDAQ:FGEN)
William Blair Equities Analysts Increase Earnings Estimates for FibroGen, Inc. (NASDAQ:FGEN)
FibroGen, Inc. (NASDAQ:FGEN – Get Rating) – Equities researchers at William Blair increased their Q3 2022 earnings per share estimates for shares of FibroGen in a note issued to investors on Monday, August 8th. William Blair analyst A. Hsieh now expects that the biopharmaceutical company will post earnings of ($0.58) per share for the quarter, up from their previous forecast of ($0.73). The consensus estimate for FibroGen's current full-year earnings is ($3.39) per share. William Blair also issued estimates for FibroGen's Q4 2022 earnings at ($0.55) EPS, FY2022 earnings at ($2.58) EPS, Q1 2023 earnings at ($0.53) EPS, Q2 2023 earnings at ($0.53) EPS, Q3 2023 earnings at ($0.52) EPS, Q4 2023 earnings at ($0.50) EPS, FY2023 earnings at ($2.07) EPS and FY2024 earnings at ($1.63) EPS.
FibroGen，Inc.(纳斯达克：FDEN-GET评级)-威廉·布莱尔的股票研究人员在8月8日星期一发给投资者的一份报告中上调了对FibroGen股票2022年第三季度每股收益的预期。William Blair分析师A.Hsieh现在预计，这家生物制药公司将公布本季度每股收益(0.58美元)，高于此前预测的(0.73美元)。对FibroGen目前全年收益的普遍预期为每股3.39美元。威廉·布莱尔还发布了对FibroGen 2022年第四季度每股收益(0.55美元)、2022财年每股收益(2.58美元)、2023年第一季度每股收益(0.53美元)、2023年第二季度每股收益(0.53美元)、2023年第三季度每股收益(0.52美元)、2023年第四季度每股收益(0.50美元)、2023财年每股收益(2.07美元)和2024财年每股收益(1.63美元)的预期。
FibroGen (NASDAQ:FGEN – Get Rating) last announced its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.94) by $0.16. FibroGen had a negative return on equity of 100.51% and a negative net margin of 83.64%. The firm had revenue of $29.81 million for the quarter, compared to the consensus estimate of $36.15 million. During the same period in the previous year, the business earned ($1.45) EPS. The firm's revenue for the quarter was up 22.3% on a year-over-year basis.
FibroGen(纳斯达克：FDEN-GET评级)上一次公布财报是在8月8日星期一。这家生物制药公司公布了本季度每股收益(0.78美元)，比普遍预期的(0.94美元)高出0.16美元。FibroGen的净资产回报率为负100.51%，净利润率为负83.64%。该公司本季度营收为2981万美元，而市场普遍预期为3615万美元。去年同期，该业务的每股收益为1.45美元。该公司当季营收较上年同期增长22.3%。
FibroGen Price Performance
FibroGen性价比
Shares of FGEN stock opened at $14.05 on Thursday. FibroGen has a 1-year low of $7.81 and a 1-year high of $16.91. The stock's fifty day moving average price is $11.72 and its 200 day moving average price is $12.01. The company has a market cap of $1.31 billion, a price-to-earnings ratio of -5.93 and a beta of 0.87.
Fgen股票周四开盘报14.05美元。FibroGen的一年低点为7.81美元，一年高位为16.91美元。该股的50日移动均线价格为11.72美元，200日移动均线价格为12.01美元。该公司市值13.1亿美元，市盈率为-5.93倍，贝塔系数为0.87。
Institutional Trading of FibroGen
FibroGen的机构交易
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. lifted its position in FibroGen by 235.9% during the 4th quarter. Point72 Asset Management L.P. now owns 3,732,594 shares of the biopharmaceutical company's stock worth $52,630,000 after acquiring an additional 2,621,494 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of FibroGen by 17.9% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 69,170 shares of the biopharmaceutical company's stock valued at $975,000 after buying an additional 10,521 shares during the period. Long Focus Capital Management LLC acquired a new position in shares of FibroGen in the 4th quarter valued at about $2,390,000. Fox Run Management L.L.C. acquired a new position in shares of FibroGen in the 4th quarter valued at about $231,000. Finally, Primecap Management Co. CA lifted its holdings in shares of FibroGen by 1.5% in the 4th quarter. Primecap Management Co. CA now owns 12,989,123 shares of the biopharmaceutical company's stock valued at $183,147,000 after buying an additional 197,366 shares during the period. Institutional investors and hedge funds own 77.35% of the company's stock.
机构投资者和对冲基金最近增持或减持了该公司的股份。Point72 Asset Management L.P.在第四季度将其在FibroGen的头寸提高了235.9%。Point72 Asset Management L.P.在此期间额外收购了2,621,494股，目前拥有这家生物制药公司3,732,594股股票，价值52,630,000美元。苏黎世广东银行在第四季度增持了17.9%的FibroGen股票。Zurcher Kantonalbank苏黎世广东银行现在持有这家生物制药公司69,170股票，价值975,000美元，在此期间又购买了10,521股票。Long Focus Capital Management LLC在第四季度收购了FibroGen股票的新头寸，价值约2390,000美元。福克斯Run Management L.L.C.在第四季度收购了FibroGen的新头寸，价值约231,000美元。最后，Primecap Management Co.CA在第四季度增持了1.5%的FibroGen股票。PrimeCap Management Co.CA现在拥有这家生物制药公司12,989,123股股票，价值183,147,000美元，在此期间又购买了197,366股。机构投资者和对冲基金持有该公司77.35%的股票。
FibroGen Company Profile
FibroGen公司简介
(Get Rating)
(获取评级)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
FibroGen，Inc.是一家生物制药公司，发现、开发和商业化治疗严重未得到满足的医疗需求的疗法。该公司正在开发一种口服低氧诱导因子Pro羟基酶小分子抑制剂roxadustat，该药已在美国、欧洲、中国和日本完成了治疗慢性肾脏疾病贫血的第三阶段临床开发，并在中国完成了治疗与骨髓增生异常综合征相关的贫血的第二/第三阶段临床开发。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on FibroGen (FGEN)
- Look at Honeywell for a Steady and Diversified Stock
- Why Invest in High-Yield Dividend Stocks?
- Find and Profitably Trade Stocks at 52-Week Lows
- Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
- Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
- 免费获取StockNews.com关于FibroGen的研究报告(Fgen)
- 霍尼韦尔看好稳定和多元化的股票
- 为什么要投资高收益股利股票？
- 找到并获利于52周低点的股票交易
- 迪士尼(NYSE：DIS)的股票刚刚给了投资者一个巨大的信号
- 清洁能源法案通过后，太阳能股大放异彩
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.
接受FibroGen Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对FibroGen和相关公司的最新新闻和分析师评级的每日简要摘要。